PerkinElmer, Inc.
About PerkinElmer, Inc.
760 articles with PerkinElmer, Inc.
-
PerkinElmer Board Declares Quarterly Dividend - Jan 26, 2023
1/26/2023
The Board of Directors of PerkinElmer, Inc. declared a regular quarterly dividend of $0.07 per share of common stock.
-
PerkinElmer To Hold Earnings Call on Tuesday, February 14, 2023; Updates Fourth Quarter Outlook
1/9/2023
PerkinElmer Inc., a global leader committed to innovating for a healthier world, announced that it will release its fourth quarter and full year 2022 financial results prior to market open on Tuesday, February 14, 2023.
-
PerkinElmer Helps Accelerate Gene Therapy Research with Industry-First Ready-to-Use Viral Vector Assays
11/21/2022
PerkinElmer, Inc. , (NYSE:PKI), a global leader committed to innovating for a healthier world, today launched ready-to-use Adeno-associated Virus Vectors (AAV) Detection Kits to support researchers working on gene therapies for a variety of serious diseases.
-
PerkinElmer Announces its EONIS SCID-SMA Kit is First to Receive Marketing Authorization by U.S. FDA for SMA Screening in Newborns
11/14/2022
PerkinElmer Inc. today announced that the U.S. Food and Drug Administration (FDA) has authorized the marketing of the EONIS™ SCID-SMA assay kit for in vitro diagnostic (IVD) use by certified laboratories for the simultaneous detection of spinal muscular atrophy (SMA) and severe combined immunodeficiency (SCID) in newborns.
-
PerkinElmer to Present at 2022 Stifel Healthcare Conference
11/10/2022
PerkinElmer Inc. today announced that the Company will present at the 2022 Stifel Healthcare Conference on Wednesday, November 16, 2022 at 9:10 a.m. ET in New York, NY.
-
PerkinElmer Board Declares Quarterly Dividend payable on February 10, 2023
10/27/2022
The Board of Directors of PerkinElmer, Inc. declared a regular quarterly dividend of $0.07 per share of common stock.
-
PerkinElmer to Hold Earnings Call on Tuesday, November 8, 2022; Updates Third Quarter Outlook
10/17/2022
PerkinElmer, Inc. today announced it will release its full third quarter 2022 financial results on November 8, 2022.
-
PerkinElmer Donation Helps Significantly Expand Capacity for Sickle Cell Disease Screening in Ghana
10/13/2022
PerkinElmer contributes reliable, fast, and cost-efficient solutions to screen for the disease in collaboration with the Sickle Cell Foundation and Ghana Health Services.
-
PerkinElmer Unveils Industry-first Cell Analysis Solution to Streamline Cell and Gene Therapy Research and Manufacturing
9/26/2022
PerkinElmer, Inc. , (NYSE: PKI), a global leader committed to innovating for a healthier world, today launched the Cellaca ® PLX Image Cytometry System, a first-of-its-kind benchtop platform that enables researchers to assess multiple Critical Quality Attributes (CQAs) of cell samples in a single automated workflow.
-
The U.S. FDA had a busy week with a range of drug approvals, advisory committee meetings and classification announcements.
-
PerkinElmer’s Oxford Immunotec Receives U.S. FDA Approval for T-Cell Select to Automate Clinically Superior Tuberculosis Detection
9/22/2022
PerkinElmer’s Oxford Immunotec Receives U.S. FDA Approval for T-Cell Select to Automate Clinically Superior Tuberculosis Detection.
-
PerkinElmer to Present at Upcoming Investor Conferences
8/24/2022
PerkinElmer Inc. today announced that the Company will present at the 2022 Wells Fargo Healthcare Conference and the Baird's 2022 Global Healthcare Conference.
-
PerkinElmer Announces Finance Leadership Transition
8/17/2022
PerkinElmer, Inc. today announced that Senior Vice President and Chief Financial Officer Jamey Mock will be transitioning from the Company to pursue an outside opportunity.
-
PerkinElmer Introduces Next Generation, Automated Gas Chromatography Platform
6/21/2022
GC 2400 solution streamlines performance and delivers superior precision for high throughput environments.
-
PerkinElmer and Novartis Collaborate to Address the Unmet Need of Sickle Cell Disease in Sub-Saharan Africa
6/16/2022
PerkinElmer’s contributions to the Novartis Africa Sickle Cell Disease program will accelerate access to sickle cell disease screening and treatment across the continent.
-
PerkinElmer Expands Genomic Testing Services with Ultrarapid Whole Genome Sequencing
5/16/2022
PerkinElmer, Inc. , a global leader committed to innovating for a healthier world, today announced the availability of ultrarapid whole genome sequencing (urWGS) through PerkinElmer Genomics.
-
PerkinElmer Announces Financial Results for the First Quarter of 2022
5/3/2022
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the first quarter ended April 3, 2022.
-
PerkinElmer Board Declares Quarterly Dividend - Apr 28, 2022
4/28/2022
The Board of Directors of PerkinElmer, Inc. declared a regular quarterly dividend of $0.07 per share of common stock.
-
PerkinElmer Schedules Earnings Call for Tuesday, May 3, 2022
4/12/2022
PerkinElmer, Inc. today announced that the Company will release its first quarter 2022 financial results after market close on Tuesday, May 3, 2022.
-
PerkinElmer Expands In Vivo Instruments Portfolio with Hands-free, High-throughput Vega® Widefield Preclinical Ultrasound Imaging System
4/7/2022
PerkinElmer, Inc. announced the expansion of its in vivo imaging portfolio with the launch of the Vega® imaging system, a first-of-its kind ultrasound platform that combines hands-free, automated technology with high-throughput capability to accelerate non-invasive research and drug development studies of cancer, liver and kidney disease, cardiology and more.